ROI Financial Advisors LLC Sells 709 Shares of IDEXX Laboratories, Inc. $IDXX

ROI Financial Advisors LLC lessened its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 31.2% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,562 shares of the company’s stock after selling 709 shares during the period. ROI Financial Advisors LLC’s holdings in IDEXX Laboratories were worth $838,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Mutual of America Capital Management LLC lifted its stake in shares of IDEXX Laboratories by 79.6% in the 1st quarter. Mutual of America Capital Management LLC now owns 19,430 shares of the company’s stock valued at $8,160,000 after acquiring an additional 8,609 shares during the last quarter. Arkadios Wealth Advisors purchased a new position in IDEXX Laboratories in the 2nd quarter worth approximately $405,000. Plato Investment Management Ltd lifted its position in IDEXX Laboratories by 37.1% in the first quarter. Plato Investment Management Ltd now owns 3,087 shares of the company’s stock valued at $1,310,000 after purchasing an additional 835 shares during the last quarter. Genesis Wealth Advisors LLC bought a new stake in IDEXX Laboratories in the second quarter valued at approximately $215,000. Finally, ORG Wealth Partners LLC purchased a new stake in shares of IDEXX Laboratories during the second quarter valued at approximately $273,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on IDXX shares. UBS Group lifted their target price on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a research note on Tuesday. Wall Street Zen cut shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Sunday, September 28th. Stifel Nicolaus set a $775.00 target price on shares of IDEXX Laboratories in a report on Monday. Jefferies Financial Group reissued a “buy” rating and issued a $830.00 target price on shares of IDEXX Laboratories in a research note on Tuesday. Finally, Morgan Stanley upped their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the company an “overweight” rating in a research report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $730.50.

IDEXX Laboratories Trading Down 0.3%

Shares of IDXX opened at $720.21 on Thursday. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $735.00. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. The firm’s 50-day moving average price is $642.72 and its 200-day moving average price is $575.17. The firm has a market capitalization of $57.62 billion, a price-to-earnings ratio of 59.97, a PEG ratio of 4.06 and a beta of 1.62.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Monday, November 3rd. The company reported $3.40 EPS for the quarter, topping the consensus estimate of $3.14 by $0.26. The business had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. IDEXX Laboratories’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period last year, the business posted $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 2,187 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the sale, the director owned 262 shares in the company, valued at approximately $169,600.46. The trade was a 89.30% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Michael G. Erickson sold 406 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total transaction of $263,883.76. Following the completion of the sale, the executive vice president directly owned 11,287 shares in the company, valued at $7,336,098.52. This represents a 3.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 9,243 shares of company stock valued at $6,018,650. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.